205 related articles for article (PubMed ID: 26985715)
21. RUNX3 directly interacts with intracellular domain of Notch1 and suppresses Notch signaling in hepatocellular carcinoma cells.
Gao J; Chen Y; Wu KC; Liu J; Zhao YQ; Pan YL; Du R; Zheng GR; Xiong YM; Xu HL; Fan DM
Exp Cell Res; 2010 Jan; 316(2):149-57. PubMed ID: 19800882
[TBL] [Abstract][Full Text] [Related]
22. Loss of runt-related transcription factor 3 expression associated with human hepatocellular carcinoma progression and prognosis.
Li J; Jiang X
Asian Pac J Cancer Prev; 2011; 12(9):2285-90. PubMed ID: 22296371
[TBL] [Abstract][Full Text] [Related]
23. Decreased expression and frequent allelic inactivation of the RUNX3 gene at 1p36 in human hepatocellular carcinoma.
Mori T; Nomoto S; Koshikawa K; Fujii T; Sakai M; Nishikawa Y; Inoue S; Takeda S; Kaneko T; Nakao A
Liver Int; 2005 Apr; 25(2):380-8. PubMed ID: 15780064
[TBL] [Abstract][Full Text] [Related]
24. Characterization and resistance mechanisms of a 5-fluorouracil- resistant hepatocellular carcinoma cell line.
Gu W; Fang FF; Li B; Cheng BB; Ling CQ
Asian Pac J Cancer Prev; 2012; 13(9):4807-14. PubMed ID: 23167424
[TBL] [Abstract][Full Text] [Related]
25. Drug efflux transporter multidrug resistance-associated protein 5 affects sensitivity of pancreatic cancer cell lines to the nucleoside anticancer drug 5-fluorouracil.
Nambaru PK; Hübner T; Köck K; Mews S; Grube M; Payen L; Guitton J; Sendler M; Jedlitschky G; Rimmbach C; Rosskopf D; Kowalczyk DW; Kroemer HK; Weiss FU; Mayerle J; Lerch MM; Ritter CA
Drug Metab Dispos; 2011 Jan; 39(1):132-9. PubMed ID: 20930123
[TBL] [Abstract][Full Text] [Related]
26. Loss of runt-related transcription factor 3 causes development and progression of hepatocellular carcinoma.
Shiraha H; Nishina S; Yamamoto K
J Cell Biochem; 2011 Mar; 112(3):745-9. PubMed ID: 21328447
[TBL] [Abstract][Full Text] [Related]
27. Opsin3 sensitizes hepatocellular carcinoma cells to 5-fluorouracil treatment by regulating the apoptotic pathway.
Jiao J; Hong S; Zhang J; Ma L; Sun Y; Zhang D; Shen B; Zhu C
Cancer Lett; 2012 Jul; 320(1):96-103. PubMed ID: 22313545
[TBL] [Abstract][Full Text] [Related]
28. The combination of glycyrrhizin and lamivudine can reverse the cisplatin resistance in hepatocellular carcinoma cells through inhibition of multidrug resistance-associated proteins.
Wakamatsu T; Nakahashi Y; Hachimine D; Seki T; Okazaki K
Int J Oncol; 2007 Dec; 31(6):1465-72. PubMed ID: 17982673
[TBL] [Abstract][Full Text] [Related]
29. Changes in the Expression of Various Transporters as Influencing Factors of Resistance to Cisplatin.
Kishimoto S; Yasuda M; Fukushima S
Anticancer Res; 2017 Oct; 37(10):5477-5484. PubMed ID: 28982859
[TBL] [Abstract][Full Text] [Related]
30. [Expression and implication of multidrug resistance associated -protein gene in primary hepatocellular carcinoma].
Wang BL; Chen XP; Zhai SP
Zhonghua Gan Zang Bing Za Zhi; 2003 Oct; 11(10):609-11. PubMed ID: 14572339
[TBL] [Abstract][Full Text] [Related]
31. Protein phosphatase 2A-B55δ enhances chemotherapy sensitivity of human hepatocellular carcinoma under the regulation of microRNA-133b.
Zhuang Q; Zhou T; He C; Zhang S; Qiu Y; Luo B; Zhao R; Liu H; Lin Y; Lin Z
J Exp Clin Cancer Res; 2016 Apr; 35():67. PubMed ID: 27074866
[TBL] [Abstract][Full Text] [Related]
32. Epithelial cell adhesion molecule in human hepatocellular carcinoma cell lines: a target of chemoresistence.
Li Y; Farmer RW; Yang Y; Martin RC
BMC Cancer; 2016 Mar; 16():228. PubMed ID: 26984381
[TBL] [Abstract][Full Text] [Related]
33. Increased expression of an ATP-binding cassette superfamily transporter, multidrug resistance protein 2, in human colorectal carcinomas.
Hinoshita E; Uchiumi T; Taguchi K; Kinukawa N; Tsuneyoshi M; Maehara Y; Sugimachi K; Kuwano M
Clin Cancer Res; 2000 Jun; 6(6):2401-7. PubMed ID: 10873092
[TBL] [Abstract][Full Text] [Related]
34. Multidrug resistance-associated protein 2 determines the efficacy of cisplatin in patients with hepatocellular carcinoma.
Korita PV; Wakai T; Shirai Y; Matsuda Y; Sakata J; Takamura M; Yano M; Sanpei A; Aoyagi Y; Hatakeyama K; Ajioka Y
Oncol Rep; 2010 Apr; 23(4):965-72. PubMed ID: 20204280
[TBL] [Abstract][Full Text] [Related]
35. MicroRNA profiles in cisplatin-induced apoptosis of hepatocellular carcinoma cells.
Miyata M; Morishita A; Sakamoto T; Katsura A; Kato K; Nishioka T; Toyota Y; Fujita K; Maeda E; Nomura T; Tani J; Miyoshi H; Yoneyama H; Kobara H; Fujiwara S; Nishiyama N; Iwama H; Himoto T; Hirashima M; Masaki T
Int J Oncol; 2015 Aug; 47(2):535-42. PubMed ID: 26060089
[TBL] [Abstract][Full Text] [Related]
36. Identification of genes associated with sensitivity to 5-fluorouracil and cisplatin in hepatoma cells.
Hoshida Y; Moriyama M; Otsuka M; Kato N; Goto T; Taniguchi H; Shiratori Y; Seki N; Omata M
J Gastroenterol; 2002 Nov; 37 Suppl 14():92-5. PubMed ID: 12572874
[TBL] [Abstract][Full Text] [Related]
37. BCAT1, a key prognostic predictor of hepatocellular carcinoma, promotes cell proliferation and induces chemoresistance to cisplatin.
Zheng YH; Hu WJ; Chen BC; Grahn TH; Zhao YR; Bao HL; Zhu YF; Zhang QY
Liver Int; 2016 Dec; 36(12):1836-1847. PubMed ID: 27246112
[TBL] [Abstract][Full Text] [Related]
38. [Reversion of multidrug resistance of human gastric cancer SGC7901/DDP cells by E2F-1 gene silencing].
Lian C; Yang J; Wang X; Xie Y; Xiao Q
Zhonghua Zhong Liu Za Zhi; 2014 Mar; 36(3):171-6. PubMed ID: 24785275
[TBL] [Abstract][Full Text] [Related]
39. The monoclonal antibody CH12 augments 5-fluorouracil-induced growth suppression of hepatocellular carcinoma xenografts expressing epidermal growth factor receptor variant III.
Jiang H; Dong Q; Luo X; Shi B; Wang H; Gao H; Kong J; Zhang J; Li Z
Cancer Lett; 2014 Jan; 342(1):113-20. PubMed ID: 24007863
[TBL] [Abstract][Full Text] [Related]
40. Enhancement of anti-tumor effects of 5-fluorouracil on hepatocellular carcinoma by low-intensity ultrasound.
Hu Z; Lv G; Li Y; Li E; Li H; Zhou Q; Yang B; Cao W
J Exp Clin Cancer Res; 2016 Apr; 35():71. PubMed ID: 27102814
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
